While Wall Street analysts remain cautious on Hims & Hers Health (HIMS), TipRanks’ A.I. Stock Analysis tool shows strong ...

Doctors report insurance cuts are forcing many U.S. patients on Wegovy and Zepbound to pay high out-of-pocket costs.

HIMS records subscriber surge and revenue growth in second-quarter 2025, but rising costs strain gross margins.

We recently published 10 Stocks That Vanished in Value Hims & Hers Health, Inc. (NYSE:HIMS) is one of the worst-performing stocks on Tuesday. Shares of telehealth company Hims & Hers Health dropped by ...

Dudum is still the largest individual holder of Hims & Hers’ stock, with the latest Form 4 showing that he owned 8 million ...